Pharma rages at 'crude' Cancer Drugs Fund overhaul
This article was originally published in Scrip
Executive Summary
Industry has expressed its disappointment over a new set of proposals designed to slim down the list of drugs funded by England's Cancer Drugs Fund (CDF), which will put the products through a second cost-effectiveness assessment deemed "crude" by the Association of the British Pharmaceutical Industry.